[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fibpL4BhLHNhDv4RdblWfTEfS9hp90W5Ubvd33e6SNVg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":46,"rows":53},"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran",[4],142,false,15,10,18524,2,95,[14,17,20,23,25,27,30,32],{"name":15,"count":16},"Obesity",11,{"name":18,"count":19},"Liver Cirrhosis",7,{"name":21,"count":22},"Cirrhosis",5,{"name":24,"count":22},"Insulin Resistance",{"name":26,"count":22},"Metabolic Syndrome",{"name":28,"count":29},"Covid19",4,{"name":31,"count":29},"Malnutrition",{"name":33,"count":34},"Hemodialysis",3,[36,41],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT07018622","Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","2026-09-30","Dapagliflozin 10 MG Oral",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06380491","Melatonin's Effect on Nighttime Blood Pressure and Sleep in OSA Patients (MEBP-OSA)","2027-12-22","Melatonin 3 MG Oral",[47,48,49,50,51,52],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[54,79,102,130,156,181,206,233,251,279,306,324,349,378,406,424,442,468,486,512,547,589,614,632,657,682,706,733,751,769,797,847,873,897,915,933,958,983,1009,1037,1055,1082,1100,1118,1143,1169,1198,1216,1243,1268,1296,1323,1341,1366,1384,1410,1436,1454,1472,1497,1523,1548],{"intervention":45,"totalTrials":55,"cells":56},1,{"EARLY_PHASE1":57,"PHASE1":60,"PHASE2":62,"PHASE3":64,"PHASE4":66,"NA":77},{"trials":58,"activeCount":59},[],0,{"trials":61,"activeCount":59},[],{"trials":63,"activeCount":59},[],{"trials":65,"activeCount":59},[],{"trials":67,"activeCount":55,"soonestReadout":44},[68],{"nctId":42,"briefTitle":43,"status":69,"phases":70,"primaryCompletion":44,"completion":71,"start":72,"enrollment":73,"conditions":74,"interventions":76},"RECRUITING",[51],"2028-01-22","2023-06-22",50,[75],"Obstructive Sleep Apnea of Adult",[45],{"trials":78,"activeCount":59},[],{"intervention":40,"totalTrials":55,"cells":80},{"EARLY_PHASE1":81,"PHASE1":83,"PHASE2":85,"PHASE3":96,"PHASE4":98,"NA":100},{"trials":82,"activeCount":59},[],{"trials":84,"activeCount":59},[],{"trials":86,"activeCount":55,"soonestReadout":39},[87],{"nctId":37,"briefTitle":38,"status":69,"phases":88,"primaryCompletion":39,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":95},[49],"2026-10-30","2025-05-07",46,[93,94],"Solid Tumors","Cisplatin Nephrotoxicity",[40],{"trials":97,"activeCount":59},[],{"trials":99,"activeCount":59},[],{"trials":101,"activeCount":59},[],{"intervention":103,"totalTrials":55,"cells":104},"Acarbose",{"EARLY_PHASE1":105,"PHASE1":107,"PHASE2":109,"PHASE3":111,"PHASE4":113,"NA":128},{"trials":106,"activeCount":59},[],{"trials":108,"activeCount":59},[],{"trials":110,"activeCount":59},[],{"trials":112,"activeCount":59},[],{"trials":114,"activeCount":59},[115],{"nctId":116,"briefTitle":117,"status":118,"phases":119,"primaryCompletion":120,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":127},"NCT02355509","Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients","COMPLETED",[51],"2014-07","2010-01",21,[124,125,126],"Glucose Intolerance","Postprandial Hyperglycemia","Cardiovascular Risk Factor",[103],{"trials":129,"activeCount":59},[],{"intervention":131,"totalTrials":55,"cells":132},"Sitagliptin phosphate",{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":139,"PHASE4":141,"NA":154},{"trials":134,"activeCount":59},[],{"trials":136,"activeCount":59},[],{"trials":138,"activeCount":59},[],{"trials":140,"activeCount":59},[],{"trials":142,"activeCount":59},[143],{"nctId":144,"briefTitle":145,"status":118,"phases":146,"primaryCompletion":147,"completion":148,"start":149,"enrollment":150,"conditions":151,"interventions":153},"NCT00847080","Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism",[51],"2010-12","2011-03","2008-12",20,[152],"Reactive Hypoglycemia",[131],{"trials":155,"activeCount":59},[],{"intervention":157,"totalTrials":55,"cells":158},"Conjugated equine estrogens 0.625 mg\u002Fd + MPA 5 mg\u002Fd\u002F10d",{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":165,"PHASE4":167,"NA":179},{"trials":160,"activeCount":59},[],{"trials":162,"activeCount":59},[],{"trials":164,"activeCount":59},[],{"trials":166,"activeCount":59},[],{"trials":168,"activeCount":59},[169],{"nctId":170,"briefTitle":171,"status":118,"phases":172,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":178},"NCT00392093","Effect of Hormone Replacement Therapy on Lupus Activity",[51],"2001-12","1997-11",108,[177],"Systemic Lupus Erythematosus",[157],{"trials":180,"activeCount":59},[],{"intervention":182,"totalTrials":55,"cells":183},"Metformin",{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":190,"PHASE4":192,"NA":204},{"trials":185,"activeCount":59},[],{"trials":187,"activeCount":59},[],{"trials":189,"activeCount":59},[],{"trials":191,"activeCount":59},[],{"trials":193,"activeCount":59},[194],{"nctId":195,"briefTitle":196,"status":118,"phases":197,"primaryCompletion":198,"completion":199,"start":200,"enrollment":73,"conditions":201,"interventions":203},"NCT01650181","Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis",[51],"2014-03","2014-06","2011-11",[202],"Liver Disease",[182,182],{"trials":205,"activeCount":59},[],{"intervention":207,"totalTrials":55,"cells":208},"Spironolactone 100mg",{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":215,"PHASE4":217,"NA":231},{"trials":210,"activeCount":59},[],{"trials":212,"activeCount":59},[],{"trials":214,"activeCount":59},[],{"trials":216,"activeCount":59},[],{"trials":218,"activeCount":59},[219],{"nctId":220,"briefTitle":221,"status":222,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":229},"NCT01843309","Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin B","TERMINATED",[51],"2015-03","2013-05",36,[228],"Patients With Fungic Infections",[207,230],"Spironolactone 200mg",{"trials":232,"activeCount":59},[],{"intervention":230,"totalTrials":55,"cells":234},{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":241,"PHASE4":243,"NA":249},{"trials":236,"activeCount":59},[],{"trials":238,"activeCount":59},[],{"trials":240,"activeCount":59},[],{"trials":242,"activeCount":59},[],{"trials":244,"activeCount":59},[245],{"nctId":220,"briefTitle":221,"status":222,"phases":246,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":247,"interventions":248},[51],[228],[207,230],{"trials":250,"activeCount":59},[],{"intervention":252,"totalTrials":55,"cells":253},"Metadoxine",{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":262,"NA":277},{"trials":255,"activeCount":59},[],{"trials":257,"activeCount":59},[],{"trials":259,"activeCount":59},[],{"trials":261,"activeCount":59},[],{"trials":263,"activeCount":59},[264],{"nctId":265,"briefTitle":266,"status":267,"phases":268,"primaryCompletion":269,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":276},"NCT02051842","Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis","UNKNOWN",[51],"2020-01","2020-12","2016-01",100,[274,275],"NAFLD","Pre-diabetes",[252],{"trials":278,"activeCount":59},[],{"intervention":280,"totalTrials":55,"cells":281},"ezetimibe\u002Fsimvastatin 10\u002F20 mg + placebo",{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":290,"NA":304},{"trials":283,"activeCount":59},[],{"trials":285,"activeCount":59},[],{"trials":287,"activeCount":59},[],{"trials":289,"activeCount":59},[],{"trials":291,"activeCount":59},[292],{"nctId":293,"briefTitle":294,"status":295,"phases":296,"primaryCompletion":297,"completion":297,"start":298,"enrollment":59,"conditions":299,"interventions":302},"NCT00738985","Efficacy of Ezetimibe\u002FSimvastatin 10\u002F20 mg and MK0524A (1-2 g\u002FDay) in Mixed Hyperlipidemia and Two or More Risk Factors","WITHDRAWN",[51],"2010-09","2009-11",[300,301],"Cardiovascular Diseases","Hyperlipidemia",[280,303],"ezetimibe\u002Fsimvastatin 10\u002F20 mg + MK0524A",{"trials":305,"activeCount":59},[],{"intervention":303,"totalTrials":55,"cells":307},{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":322},{"trials":309,"activeCount":59},[],{"trials":311,"activeCount":59},[],{"trials":313,"activeCount":59},[],{"trials":315,"activeCount":59},[],{"trials":317,"activeCount":59},[318],{"nctId":293,"briefTitle":294,"status":295,"phases":319,"primaryCompletion":297,"completion":297,"start":298,"enrollment":59,"conditions":320,"interventions":321},[51],[300,301],[280,303],{"trials":323,"activeCount":59},[],{"intervention":325,"totalTrials":55,"cells":326},"Glyburide",{"EARLY_PHASE1":327,"PHASE1":329,"PHASE2":331,"PHASE3":333,"PHASE4":335,"NA":347},{"trials":328,"activeCount":59},[],{"trials":330,"activeCount":59},[],{"trials":332,"activeCount":59},[],{"trials":334,"activeCount":59},[],{"trials":336,"activeCount":59},[337],{"nctId":338,"briefTitle":339,"status":118,"phases":340,"primaryCompletion":341,"completion":342,"start":148,"enrollment":343,"conditions":344,"interventions":346},"NCT01456650","R230C and C230C Variants of ABCA1 and Glyburide Response",[51],"2012-11","2012-12",85,[345],"Type 2 Diabetes",[325],{"trials":348,"activeCount":59},[],{"intervention":350,"totalTrials":55,"cells":351},"Cholecalciferol",{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":356,"PHASE3":358,"PHASE4":360,"NA":376},{"trials":353,"activeCount":59},[],{"trials":355,"activeCount":59},[],{"trials":357,"activeCount":59},[],{"trials":359,"activeCount":59},[],{"trials":361,"activeCount":59},[362],{"nctId":363,"briefTitle":364,"status":267,"phases":365,"primaryCompletion":366,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":375},"NCT02598635","Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis",[51],"2016-10","2017-06","2015-10",58,[371,372,373,374],"Vitamin D Deficiency","Vascular Calcification","Renal Insufficiency","End Stage Renal Failure on Dialysis",[350],{"trials":377,"activeCount":59},[],{"intervention":379,"totalTrials":55,"cells":380},"Fosfomycin disodium",{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":387,"PHASE4":389,"NA":404},{"trials":382,"activeCount":59},[],{"trials":384,"activeCount":59},[],{"trials":386,"activeCount":59},[],{"trials":388,"activeCount":59},[],{"trials":390,"activeCount":59},[391],{"nctId":392,"briefTitle":393,"status":118,"phases":394,"primaryCompletion":395,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":401},"NCT03235947","Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients",[51],"2017-11-06","2016-09-07",82,[399,400],"Urinary Tract Infection","Asymptomatic Bacteriuria",[379,402,403],"Trimethoprim \u002F Sulfamethoxazole","Intravenous placebo",{"trials":405,"activeCount":59},[],{"intervention":402,"totalTrials":55,"cells":407},{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":412,"PHASE3":414,"PHASE4":416,"NA":422},{"trials":409,"activeCount":59},[],{"trials":411,"activeCount":59},[],{"trials":413,"activeCount":59},[],{"trials":415,"activeCount":59},[],{"trials":417,"activeCount":59},[418],{"nctId":392,"briefTitle":393,"status":118,"phases":419,"primaryCompletion":395,"completion":395,"start":396,"enrollment":397,"conditions":420,"interventions":421},[51],[399,400],[379,402,403],{"trials":423,"activeCount":59},[],{"intervention":403,"totalTrials":55,"cells":425},{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":434,"NA":440},{"trials":427,"activeCount":59},[],{"trials":429,"activeCount":59},[],{"trials":431,"activeCount":59},[],{"trials":433,"activeCount":59},[],{"trials":435,"activeCount":59},[436],{"nctId":392,"briefTitle":393,"status":118,"phases":437,"primaryCompletion":395,"completion":395,"start":396,"enrollment":397,"conditions":438,"interventions":439},[51],[399,400],[379,402,403],{"trials":441,"activeCount":59},[],{"intervention":443,"totalTrials":55,"cells":444},"zidovudine+lamivudine+lopinavir\u002Fritonavir",{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":451,"PHASE4":453,"NA":466},{"trials":446,"activeCount":59},[],{"trials":448,"activeCount":59},[],{"trials":450,"activeCount":59},[],{"trials":452,"activeCount":59},[],{"trials":454,"activeCount":59},[455],{"nctId":456,"briefTitle":457,"status":267,"phases":458,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":464},"NCT00162643","PI Vs. NNRTI Based Therapy for HIV Advanced Disease",[51],"2007-12","2004-12",300,[463],"Acquired Immunodeficiency Syndrome",[443,465],"zidovudine + lamivudine + efavirenz",{"trials":467,"activeCount":59},[],{"intervention":465,"totalTrials":55,"cells":469},{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":474,"PHASE3":476,"PHASE4":478,"NA":484},{"trials":471,"activeCount":59},[],{"trials":473,"activeCount":59},[],{"trials":475,"activeCount":59},[],{"trials":477,"activeCount":59},[],{"trials":479,"activeCount":59},[480],{"nctId":456,"briefTitle":457,"status":267,"phases":481,"completion":459,"start":460,"enrollment":461,"conditions":482,"interventions":483},[51],[463],[443,465],{"trials":485,"activeCount":59},[],{"intervention":487,"totalTrials":55,"cells":488},"Trimethoprim-Sulfamethoxazole",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":495,"PHASE4":497,"NA":510},{"trials":490,"activeCount":59},[],{"trials":492,"activeCount":59},[],{"trials":494,"activeCount":59},[],{"trials":496,"activeCount":59},[],{"trials":498,"activeCount":59},[499],{"nctId":500,"briefTitle":501,"status":267,"phases":502,"primaryCompletion":503,"completion":504,"start":505,"enrollment":506,"conditions":507,"interventions":509},"NCT03042260","Prophylactic Trimethoprim\u002FSulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous",[51],"2021-02","2021-08","2017-03-01",310,[508],"Lupus Erythematosus, Systemic",[487],{"trials":511,"activeCount":59},[],{"intervention":513,"totalTrials":11,"cells":514},"Pirfenidone",{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":521,"PHASE4":543,"NA":545},{"trials":516,"activeCount":59},[],{"trials":518,"activeCount":59},[],{"trials":520,"activeCount":59},[],{"trials":522,"activeCount":59},[523,532],{"nctId":524,"briefTitle":525,"status":118,"phases":526,"primaryCompletion":527,"completion":527,"start":528,"enrollment":226,"conditions":529,"interventions":531},"NCT02222376","Effect of Topic Pirfenidone in Diabetic Ulcers",[50],"2015-04","2013-10",[530],"Diabetic Foot Ulcers",[513],{"nctId":533,"briefTitle":534,"status":118,"phases":535,"primaryCompletion":536,"completion":536,"start":537,"enrollment":538,"conditions":539,"interventions":542},"NCT02689778","Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy",[50],"2019-12","2016-03",62,[540,541],"Diabetic Nephropathy","Albuminuria",[513],{"trials":544,"activeCount":59},[],{"trials":546,"activeCount":59},[],{"intervention":548,"totalTrials":11,"cells":549},"Pyridostigmine Bromide",{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":571,"PHASE4":585,"NA":587},{"trials":551,"activeCount":59},[],{"trials":553,"activeCount":59},[],{"trials":555,"activeCount":59},[556],{"nctId":557,"briefTitle":558,"status":559,"phases":560,"primaryCompletion":561,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":570},"NCT03312244","Pyridostigmine as Immunomodulator in People Living With HIV","SUSPENDED",[49],"2021-06-30","2022-06-30","2019-07-01",60,[566,567,568,569],"HIV-1-infection","CD4+ T Lymphocytopenia","Immune Deficiency","Immuno-senescence",[548],{"trials":572,"activeCount":59},[573],{"nctId":574,"briefTitle":575,"status":267,"phases":576,"primaryCompletion":577,"completion":578,"start":579,"enrollment":580,"conditions":581,"interventions":584},"NCT04343963","Pyridostigmine in Severe SARS-CoV-2 Infection",[49,50],"2020-09-30","2021-04-30","2020-04-04",436,[582,583],"COVID-19","SARS-CoV-2",[548],{"trials":586,"activeCount":59},[],{"trials":588,"activeCount":59},[],{"intervention":590,"totalTrials":55,"cells":591},"Bezafibrate",{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":598,"PHASE4":610,"NA":612},{"trials":593,"activeCount":59},[],{"trials":595,"activeCount":59},[],{"trials":597,"activeCount":59},[],{"trials":599,"activeCount":59},[600],{"nctId":601,"briefTitle":602,"status":267,"phases":603,"primaryCompletion":604,"completion":536,"start":366,"enrollment":605,"conditions":606,"interventions":608},"NCT02937012","Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders",[50],"2019-04",34,[607],"Primary Biliary Cirrhosis",[590,609],"Ursodeoxycholic Acid",{"trials":611,"activeCount":59},[],{"trials":613,"activeCount":59},[],{"intervention":609,"totalTrials":55,"cells":615},{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":622,"PHASE4":628,"NA":630},{"trials":617,"activeCount":59},[],{"trials":619,"activeCount":59},[],{"trials":621,"activeCount":59},[],{"trials":623,"activeCount":59},[624],{"nctId":601,"briefTitle":602,"status":267,"phases":625,"primaryCompletion":604,"completion":536,"start":366,"enrollment":605,"conditions":626,"interventions":627},[50],[607],[590,609],{"trials":629,"activeCount":59},[],{"trials":631,"activeCount":59},[],{"intervention":633,"totalTrials":55,"cells":634},"Spironolactone 25 mg",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":641,"PHASE4":653,"NA":655},{"trials":636,"activeCount":59},[],{"trials":638,"activeCount":59},[],{"trials":640,"activeCount":59},[],{"trials":642,"activeCount":59},[643],{"nctId":644,"briefTitle":645,"status":267,"phases":646,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":650,"interventions":652},"NCT03206658","Spironolactone on Acute Kidney Injury in Critically Ill Patients",[50],"2019-12-31","2017-08-01",90,[651],"Acute Kidney Injury",[633],{"trials":654,"activeCount":59},[],{"trials":656,"activeCount":59},[],{"intervention":658,"totalTrials":55,"cells":659},"convalescent plasma",{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":678,"NA":680},{"trials":661,"activeCount":59},[],{"trials":663,"activeCount":59},[],{"trials":665,"activeCount":59},[],{"trials":667,"activeCount":59},[668],{"nctId":669,"briefTitle":670,"status":267,"phases":671,"primaryCompletion":672,"completion":673,"start":674,"enrollment":675,"conditions":676,"interventions":677},"NCT04388410","Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19",[49,50],"2020-11-30","2020-12-31","2020-08-25",410,[582],[658],{"trials":679,"activeCount":59},[],{"trials":681,"activeCount":59},[],{"intervention":683,"totalTrials":55,"cells":684},"Haloperidol",{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":691,"PHASE4":702,"NA":704},{"trials":686,"activeCount":59},[],{"trials":688,"activeCount":59},[],{"trials":690,"activeCount":59},[],{"trials":692,"activeCount":59},[693],{"nctId":694,"briefTitle":695,"status":267,"phases":696,"primaryCompletion":697,"completion":698,"start":271,"enrollment":564,"conditions":699,"interventions":701},"NCT02345902","Treatment of Hypoactive Delirium and Outcome Measures",[50],"2018-03","2018-12",[700],"Hypoactive Delirium",[683],{"trials":703,"activeCount":59},[],{"trials":705,"activeCount":59},[],{"intervention":707,"totalTrials":55,"cells":708},"PEG-3350 group 2",{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":713,"PHASE3":715,"PHASE4":729,"NA":731},{"trials":710,"activeCount":59},[],{"trials":712,"activeCount":59},[],{"trials":714,"activeCount":59},[],{"trials":716,"activeCount":59},[717],{"nctId":718,"briefTitle":719,"status":118,"phases":720,"primaryCompletion":721,"completion":721,"start":722,"enrollment":723,"conditions":724,"interventions":726},"NCT01929590","Low-volume Polyethylene Glycol Bowel Preparation for Colonoscopy",[50],"2012-06","2011-10",180,[725],"Bowel Preparation for Colonoscopy",[707,727,728],"PEG-3350 group 1","PEG-3350 group 3",{"trials":730,"activeCount":59},[],{"trials":732,"activeCount":59},[],{"intervention":727,"totalTrials":55,"cells":734},{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":741,"PHASE4":747,"NA":749},{"trials":736,"activeCount":59},[],{"trials":738,"activeCount":59},[],{"trials":740,"activeCount":59},[],{"trials":742,"activeCount":59},[743],{"nctId":718,"briefTitle":719,"status":118,"phases":744,"primaryCompletion":721,"completion":721,"start":722,"enrollment":723,"conditions":745,"interventions":746},[50],[725],[707,727,728],{"trials":748,"activeCount":59},[],{"trials":750,"activeCount":59},[],{"intervention":728,"totalTrials":55,"cells":752},{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":757,"PHASE3":759,"PHASE4":765,"NA":767},{"trials":754,"activeCount":59},[],{"trials":756,"activeCount":59},[],{"trials":758,"activeCount":59},[],{"trials":760,"activeCount":59},[761],{"nctId":718,"briefTitle":719,"status":118,"phases":762,"primaryCompletion":721,"completion":721,"start":722,"enrollment":723,"conditions":763,"interventions":764},[50],[725],[707,727,728],{"trials":766,"activeCount":59},[],{"trials":768,"activeCount":59},[],{"intervention":770,"totalTrials":55,"cells":771},"Dapagliflozin",{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":778,"PHASE4":793,"NA":795},{"trials":773,"activeCount":59},[],{"trials":775,"activeCount":59},[],{"trials":777,"activeCount":59},[],{"trials":779,"activeCount":59},[780],{"nctId":781,"briefTitle":782,"status":267,"phases":783,"primaryCompletion":784,"completion":785,"start":786,"enrollment":272,"conditions":787,"interventions":792},"NCT05713851","Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study",[49,50],"2024-12-01","2025-01-01","2023-01-01",[788,789,790,791],"AKI - Acute Kidney Injury","Biomarkers","Transition to CKD","CKD",[770],{"trials":794,"activeCount":59},[],{"trials":796,"activeCount":59},[],{"intervention":798,"totalTrials":34,"cells":799},"Cyclophosphamide",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":841,"PHASE4":843,"NA":845},{"trials":801,"activeCount":59},[],{"trials":803,"activeCount":59},[],{"trials":805,"activeCount":59},[806,820,830],{"nctId":807,"briefTitle":808,"status":267,"phases":809,"primaryCompletion":810,"completion":811,"start":812,"enrollment":150,"conditions":813,"interventions":816},"NCT02670109","Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients",[49],"2020-11","2021-11","2018-02-01",[814,815],"Triple-Negative Invasive Breast Carcinoma","Residual Tumor",[817,798,818,819],"Carmustine","Carboplatin","Busulfan",{"nctId":821,"briefTitle":822,"status":267,"phases":823,"primaryCompletion":810,"completion":811,"start":824,"enrollment":150,"conditions":825,"interventions":828},"NCT02605460","Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission",[49],"2014-02",[826,827],"Acute Myeloid Leukemia","Acute Lymphoid Leukemia",[819,798,829],"CXCR4 Antagonist",{"nctId":831,"briefTitle":832,"status":267,"phases":833,"primaryCompletion":834,"completion":835,"start":836,"enrollment":8,"conditions":837,"interventions":839},"NCT03339700","Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia",[49],"2020-09","2021-09","2018-09-15",[838],"Acute Lymphoblastic Leukemia, Adult",[840,819,798],"Gemcitabine",{"trials":842,"activeCount":59},[],{"trials":844,"activeCount":59},[],{"trials":846,"activeCount":59},[],{"intervention":819,"totalTrials":34,"cells":848},{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":867,"PHASE4":869,"NA":871},{"trials":850,"activeCount":59},[],{"trials":852,"activeCount":59},[],{"trials":854,"activeCount":59},[855,859,863],{"nctId":807,"briefTitle":808,"status":267,"phases":856,"primaryCompletion":810,"completion":811,"start":812,"enrollment":150,"conditions":857,"interventions":858},[49],[814,815],[817,798,818,819],{"nctId":821,"briefTitle":822,"status":267,"phases":860,"primaryCompletion":810,"completion":811,"start":824,"enrollment":150,"conditions":861,"interventions":862},[49],[826,827],[819,798,829],{"nctId":831,"briefTitle":832,"status":267,"phases":864,"primaryCompletion":834,"completion":835,"start":836,"enrollment":8,"conditions":865,"interventions":866},[49],[838],[840,819,798],{"trials":868,"activeCount":59},[],{"trials":870,"activeCount":59},[],{"trials":872,"activeCount":59},[],{"intervention":874,"totalTrials":55,"cells":875},"Infusion IV of Mesenchymal Stem cells",{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":891,"PHASE4":893,"NA":895},{"trials":877,"activeCount":59},[],{"trials":879,"activeCount":59},[],{"trials":881,"activeCount":59},[882],{"nctId":883,"briefTitle":884,"status":267,"phases":885,"primaryCompletion":578,"completion":886,"start":887,"enrollment":9,"conditions":888,"interventions":890},"NCT04416139","Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19",[49],"2021-05-01","2020-05-01",[889],"Covid 19",[874],{"trials":892,"activeCount":59},[],{"trials":894,"activeCount":59},[],{"trials":896,"activeCount":59},[],{"intervention":817,"totalTrials":55,"cells":898},{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":903,"PHASE3":909,"PHASE4":911,"NA":913},{"trials":900,"activeCount":59},[],{"trials":902,"activeCount":59},[],{"trials":904,"activeCount":59},[905],{"nctId":807,"briefTitle":808,"status":267,"phases":906,"primaryCompletion":810,"completion":811,"start":812,"enrollment":150,"conditions":907,"interventions":908},[49],[814,815],[817,798,818,819],{"trials":910,"activeCount":59},[],{"trials":912,"activeCount":59},[],{"trials":914,"activeCount":59},[],{"intervention":818,"totalTrials":55,"cells":916},{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":927,"PHASE4":929,"NA":931},{"trials":918,"activeCount":59},[],{"trials":920,"activeCount":59},[],{"trials":922,"activeCount":59},[923],{"nctId":807,"briefTitle":808,"status":267,"phases":924,"primaryCompletion":810,"completion":811,"start":812,"enrollment":150,"conditions":925,"interventions":926},[49],[814,815],[817,798,818,819],{"trials":928,"activeCount":59},[],{"trials":930,"activeCount":59},[],{"trials":932,"activeCount":59},[],{"intervention":934,"totalTrials":55,"cells":935},"Pyridostigmine",{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":952,"PHASE4":954,"NA":956},{"trials":937,"activeCount":59},[],{"trials":939,"activeCount":59},[],{"trials":941,"activeCount":59},[942],{"nctId":943,"briefTitle":944,"status":118,"phases":945,"primaryCompletion":946,"completion":947,"start":948,"enrollment":19,"conditions":949,"interventions":951},"NCT00518154","Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response",[49],"2008-11","2009-01","2007-09",[950],"HIV Infections",[934],{"trials":953,"activeCount":59},[],{"trials":955,"activeCount":59},[],{"trials":957,"activeCount":59},[],{"intervention":959,"totalTrials":55,"cells":960},"ADSVF application in the right hand",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":962,"activeCount":59},[],{"trials":964,"activeCount":59},[],{"trials":966,"activeCount":59},[967],{"nctId":968,"briefTitle":969,"status":118,"phases":970,"primaryCompletion":971,"completion":972,"start":973,"enrollment":150,"conditions":974,"interventions":976},"NCT04387825","Safety Of Fat Micrografts With Adipose-Derived Stromal Vascular Fraction In Hands Of Patients With Systemic Sclerosis",[49],"2019-05","2020-05","2015-08-13",[975],"Systemic Sclerosis",[959],{"trials":978,"activeCount":59},[],{"trials":980,"activeCount":59},[],{"trials":982,"activeCount":59},[],{"intervention":984,"totalTrials":55,"cells":985},"Life Style Intervention + Metformin",{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":990,"PHASE3":1003,"PHASE4":1005,"NA":1007},{"trials":987,"activeCount":59},[],{"trials":989,"activeCount":59},[],{"trials":991,"activeCount":59},[992],{"nctId":993,"briefTitle":994,"status":118,"phases":995,"primaryCompletion":996,"completion":997,"start":998,"enrollment":999,"conditions":1000,"interventions":1002},"NCT05990205","Effect of the SCL16A11 Risk Haplotype on Treatments to Prevent Type 2 Diabetes",[49],"2023-12-20","2024-03-01","2018-04-17",437,[1001],"PreDiabetes",[984],{"trials":1004,"activeCount":59},[],{"trials":1006,"activeCount":59},[],{"trials":1008,"activeCount":59},[],{"intervention":1010,"totalTrials":55,"cells":1011},"Fosfomycin Tromethamine 3G Sachet",{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1031,"PHASE4":1033,"NA":1035},{"trials":1013,"activeCount":59},[],{"trials":1015,"activeCount":59},[],{"trials":1017,"activeCount":59},[1018],{"nctId":1019,"briefTitle":1020,"status":118,"phases":1021,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":1025,"interventions":1029},"NCT04209192","Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB)",[49],"2023-04-01","2020-01-01",75,[1026,1027,1028],"Urinary Tract Infections","Bladder Cancer","Urologic Surgical Procedures",[1010,1030],"Amikacin",{"trials":1032,"activeCount":59},[],{"trials":1034,"activeCount":59},[],{"trials":1036,"activeCount":59},[],{"intervention":1030,"totalTrials":55,"cells":1038},{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1043,"PHASE3":1049,"PHASE4":1051,"NA":1053},{"trials":1040,"activeCount":59},[],{"trials":1042,"activeCount":59},[],{"trials":1044,"activeCount":59},[1045],{"nctId":1019,"briefTitle":1020,"status":118,"phases":1046,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":1047,"interventions":1048},[49],[1026,1027,1028],[1010,1030],{"trials":1050,"activeCount":59},[],{"trials":1052,"activeCount":59},[],{"trials":1054,"activeCount":59},[],{"intervention":1056,"totalTrials":55,"cells":1057},"Camostat Mesilate",{"EARLY_PHASE1":1058,"PHASE1":1060,"PHASE2":1062,"PHASE3":1076,"PHASE4":1078,"NA":1080},{"trials":1059,"activeCount":59},[],{"trials":1061,"activeCount":59},[],{"trials":1063,"activeCount":59},[1064],{"nctId":1065,"briefTitle":1066,"status":222,"phases":1067,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":1070,"conditions":1071,"interventions":1074},"NCT04530617","Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients",[49],"2021-06-10","2020-10-05",246,[28,1072,1073,15],"Diabetes","Hypertension",[1056,1075],"Artemisia Annua Leaf",{"trials":1077,"activeCount":59},[],{"trials":1079,"activeCount":59},[],{"trials":1081,"activeCount":59},[],{"intervention":1075,"totalTrials":55,"cells":1083},{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1094,"PHASE4":1096,"NA":1098},{"trials":1085,"activeCount":59},[],{"trials":1087,"activeCount":59},[],{"trials":1089,"activeCount":59},[1090],{"nctId":1065,"briefTitle":1066,"status":222,"phases":1091,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":1070,"conditions":1092,"interventions":1093},[49],[28,1072,1073,15],[1056,1075],{"trials":1095,"activeCount":59},[],{"trials":1097,"activeCount":59},[],{"trials":1099,"activeCount":59},[],{"intervention":829,"totalTrials":55,"cells":1101},{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1112,"PHASE4":1114,"NA":1116},{"trials":1103,"activeCount":59},[],{"trials":1105,"activeCount":59},[],{"trials":1107,"activeCount":59},[1108],{"nctId":821,"briefTitle":822,"status":267,"phases":1109,"primaryCompletion":810,"completion":811,"start":824,"enrollment":150,"conditions":1110,"interventions":1111},[49],[826,827],[819,798,829],{"trials":1113,"activeCount":59},[],{"trials":1115,"activeCount":59},[],{"trials":1117,"activeCount":59},[],{"intervention":1119,"totalTrials":55,"cells":1120},"Comparison between Lactulose and Lactulose-Paraffin",{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1125,"PHASE3":1137,"PHASE4":1139,"NA":1141},{"trials":1122,"activeCount":59},[],{"trials":1124,"activeCount":59},[],{"trials":1126,"activeCount":59},[1127],{"nctId":1128,"briefTitle":1129,"status":118,"phases":1130,"primaryCompletion":1131,"completion":199,"start":1132,"enrollment":1133,"conditions":1134,"interventions":1136},"NCT02017119","Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients",[49],"2014-05","2011-01",40,[21,1135],"Hepatic Encephalopathy",[1119],{"trials":1138,"activeCount":59},[],{"trials":1140,"activeCount":59},[],{"trials":1142,"activeCount":59},[],{"intervention":1144,"totalTrials":55,"cells":1145},"Colchicine",{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1163,"PHASE4":1165,"NA":1167},{"trials":1147,"activeCount":59},[],{"trials":1149,"activeCount":59},[],{"trials":1151,"activeCount":59},[1152],{"nctId":1153,"briefTitle":1154,"status":222,"phases":1155,"primaryCompletion":1156,"completion":1157,"start":1158,"enrollment":1159,"conditions":1160,"interventions":1162},"NCT04367168","Colchicine in Patients With Mild and Severe Coronavirus Disease",[49],"2021-04-27","2021-08-16","2020-05-27",116,[1161],"COVID",[1144],{"trials":1164,"activeCount":59},[],{"trials":1166,"activeCount":59},[],{"trials":1168,"activeCount":59},[],{"intervention":1170,"totalTrials":55,"cells":1171},"Microbiota",{"EARLY_PHASE1":1172,"PHASE1":1174,"PHASE2":1176,"PHASE3":1192,"PHASE4":1194,"NA":1196},{"trials":1173,"activeCount":59},[],{"trials":1175,"activeCount":59},[],{"trials":1177,"activeCount":59},[1178],{"nctId":1179,"briefTitle":1180,"status":118,"phases":1181,"primaryCompletion":1182,"completion":1183,"start":1184,"enrollment":1185,"conditions":1186,"interventions":1191},"NCT07496502","Effect of Oral Microbiota on MDRO Decolonization",[48,49],"2022-06-14","2022-07-01","2022-03-31",42,[1187,1188,1189,1190,1170],"Clostridioides Difficile Infection","Drug Resistance, Bacterial","Gastrointestinal Microbiome","Multidrug-resistant Colonization",[1170],{"trials":1193,"activeCount":59},[],{"trials":1195,"activeCount":59},[],{"trials":1197,"activeCount":59},[],{"intervention":840,"totalTrials":55,"cells":1199},{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1204,"PHASE3":1210,"PHASE4":1212,"NA":1214},{"trials":1201,"activeCount":59},[],{"trials":1203,"activeCount":59},[],{"trials":1205,"activeCount":59},[1206],{"nctId":831,"briefTitle":832,"status":267,"phases":1207,"primaryCompletion":834,"completion":835,"start":836,"enrollment":8,"conditions":1208,"interventions":1209},[49],[838],[840,819,798],{"trials":1211,"activeCount":59},[],{"trials":1213,"activeCount":59},[],{"trials":1215,"activeCount":59},[],{"intervention":1217,"totalTrials":55,"cells":1218},"maraviroc",{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1227,"NA":1229},{"trials":1220,"activeCount":59},[],{"trials":1222,"activeCount":59},[],{"trials":1224,"activeCount":59},[],{"trials":1226,"activeCount":59},[],{"trials":1228,"activeCount":59},[],{"trials":1230,"activeCount":59},[1231],{"nctId":1232,"briefTitle":1233,"status":267,"phases":1234,"primaryCompletion":1235,"completion":1236,"start":1237,"enrollment":1238,"conditions":1239,"interventions":1242},"NCT00988780","Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients",[52],"2013-03","2013-04","2009-12",276,[1240,1241,950],"Immune Reconstitution Inflammatory Syndrome","HIV",[1217],{"intervention":1244,"totalTrials":55,"cells":1245},"Vitamin D",{"EARLY_PHASE1":1246,"PHASE1":1248,"PHASE2":1250,"PHASE3":1252,"PHASE4":1254,"NA":1256},{"trials":1247,"activeCount":59},[],{"trials":1249,"activeCount":59},[],{"trials":1251,"activeCount":59},[],{"trials":1253,"activeCount":59},[],{"trials":1255,"activeCount":59},[],{"trials":1257,"activeCount":59},[1258],{"nctId":1259,"briefTitle":1260,"status":222,"phases":1261,"primaryCompletion":1262,"completion":1262,"start":1263,"enrollment":1264,"conditions":1265,"interventions":1267},"NCT03356873","Impact of Correction of Vitamin D Deficiency in Oxidative Stress in Patients With Prediabetes (VICOX)",[52],"2022-07-18","2017-09-01",31,[371,124,1266,24],"Oxidative Stress",[1244],{"intervention":1269,"totalTrials":55,"cells":1270},"Infiltration of 0.5% Bupivacaine",{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1275,"PHASE3":1277,"PHASE4":1279,"NA":1281},{"trials":1272,"activeCount":59},[],{"trials":1274,"activeCount":59},[],{"trials":1276,"activeCount":59},[],{"trials":1278,"activeCount":59},[],{"trials":1280,"activeCount":59},[],{"trials":1282,"activeCount":59},[1283],{"nctId":1284,"briefTitle":1285,"status":267,"phases":1286,"primaryCompletion":1287,"start":1288,"enrollment":1289,"conditions":1290,"interventions":1295},"NCT02777866","LAW Trial -The Impact of Local Anesthetics Infiltration in Surgical Wound of Gastrointestinal Procedures",[52],"2017-01","2016-05",570,[1291,1292,1293,1294],"Surgical Site Infection","Wound Infection","Postoperative Pain","Local Anesthetics",[1269],{"intervention":1297,"totalTrials":55,"cells":1298},"Losartan",{"EARLY_PHASE1":1299,"PHASE1":1301,"PHASE2":1303,"PHASE3":1305,"PHASE4":1307,"NA":1309},{"trials":1300,"activeCount":59},[],{"trials":1302,"activeCount":59},[],{"trials":1304,"activeCount":59},[],{"trials":1306,"activeCount":59},[],{"trials":1308,"activeCount":59},[],{"trials":1310,"activeCount":59},[1311],{"nctId":1312,"briefTitle":1313,"status":267,"phases":1314,"primaryCompletion":1315,"completion":1316,"start":1317,"enrollment":1133,"conditions":1318,"interventions":1321},"NCT03526042","Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis",[52],"2019-07-31","2019-10-31","2017-09-10",[1319,1320],"Atherosclerosis","Lupus Nephritis",[1297,1322],"Enalapril",{"intervention":1322,"totalTrials":55,"cells":1324},{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1331,"PHASE4":1333,"NA":1335},{"trials":1326,"activeCount":59},[],{"trials":1328,"activeCount":59},[],{"trials":1330,"activeCount":59},[],{"trials":1332,"activeCount":59},[],{"trials":1334,"activeCount":59},[],{"trials":1336,"activeCount":59},[1337],{"nctId":1312,"briefTitle":1313,"status":267,"phases":1338,"primaryCompletion":1315,"completion":1316,"start":1317,"enrollment":1133,"conditions":1339,"interventions":1340},[52],[1319,1320],[1297,1322],{"intervention":1342,"totalTrials":55,"cells":1343},"Epinephrine",{"EARLY_PHASE1":1344,"PHASE1":1346,"PHASE2":1348,"PHASE3":1350,"PHASE4":1352,"NA":1354},{"trials":1345,"activeCount":59},[],{"trials":1347,"activeCount":59},[],{"trials":1349,"activeCount":59},[],{"trials":1351,"activeCount":59},[],{"trials":1353,"activeCount":59},[],{"trials":1355,"activeCount":59},[1356],{"nctId":1357,"briefTitle":1358,"status":222,"phases":1359,"primaryCompletion":1360,"completion":1360,"start":1288,"enrollment":1361,"conditions":1362,"interventions":1364},"NCT02959112","Epinephrine Sprayed on the Papilla Versus Sterile Water Sprayed on the Papilla for Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography",[52],"2019-06",548,[1363],"Pancreatitis, Acute",[1342,1365],"Indomethacin Rectal Suppository",{"intervention":1365,"totalTrials":55,"cells":1367},{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1374,"PHASE4":1376,"NA":1378},{"trials":1369,"activeCount":59},[],{"trials":1371,"activeCount":59},[],{"trials":1373,"activeCount":59},[],{"trials":1375,"activeCount":59},[],{"trials":1377,"activeCount":59},[],{"trials":1379,"activeCount":59},[1380],{"nctId":1357,"briefTitle":1358,"status":222,"phases":1381,"primaryCompletion":1360,"completion":1360,"start":1288,"enrollment":1361,"conditions":1382,"interventions":1383},[52],[1363],[1342,1365],{"intervention":1385,"totalTrials":55,"cells":1386},"Sofosbuvir 400 MG \u002F Velpatasvir 100 MG [Epclusa]",{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1393,"PHASE4":1395,"NA":1397},{"trials":1388,"activeCount":59},[],{"trials":1390,"activeCount":59},[],{"trials":1392,"activeCount":59},[],{"trials":1394,"activeCount":59},[],{"trials":1396,"activeCount":59},[],{"trials":1398,"activeCount":59},[1399],{"nctId":1400,"briefTitle":1401,"status":267,"phases":1402,"primaryCompletion":1403,"completion":1404,"start":1405,"enrollment":1406,"conditions":1407,"interventions":1409},"NCT05503979","Elimination of Hepatitis C Virus Among Users of Substances",[],"2023-08-15","2024-05-15","2022-11-15",1000,[1408],"Hepatitis C in Substance Users",[1385],{"intervention":1411,"totalTrials":55,"cells":1412},"Methimazole",{"EARLY_PHASE1":1413,"PHASE1":1415,"PHASE2":1417,"PHASE3":1419,"PHASE4":1421,"NA":1423},{"trials":1414,"activeCount":59},[],{"trials":1416,"activeCount":59},[],{"trials":1418,"activeCount":59},[],{"trials":1420,"activeCount":59},[],{"trials":1422,"activeCount":59},[],{"trials":1424,"activeCount":59},[1425],{"nctId":1426,"briefTitle":1427,"status":222,"phases":1428,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1264,"conditions":1431,"interventions":1433},"NCT01893450","Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment",[52],"2013-06","2008-06",[1432],"Graves Ophthalmopathy",[1411,1434,1435],"Bromocriptine","Pentoxifylline",{"intervention":1434,"totalTrials":55,"cells":1437},{"EARLY_PHASE1":1438,"PHASE1":1440,"PHASE2":1442,"PHASE3":1444,"PHASE4":1446,"NA":1448},{"trials":1439,"activeCount":59},[],{"trials":1441,"activeCount":59},[],{"trials":1443,"activeCount":59},[],{"trials":1445,"activeCount":59},[],{"trials":1447,"activeCount":59},[],{"trials":1449,"activeCount":59},[1450],{"nctId":1426,"briefTitle":1427,"status":222,"phases":1451,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1264,"conditions":1452,"interventions":1453},[52],[1432],[1411,1434,1435],{"intervention":1435,"totalTrials":55,"cells":1455},{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1460,"PHASE3":1462,"PHASE4":1464,"NA":1466},{"trials":1457,"activeCount":59},[],{"trials":1459,"activeCount":59},[],{"trials":1461,"activeCount":59},[],{"trials":1463,"activeCount":59},[],{"trials":1465,"activeCount":59},[],{"trials":1467,"activeCount":59},[1468],{"nctId":1426,"briefTitle":1427,"status":222,"phases":1469,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1264,"conditions":1470,"interventions":1471},[52],[1432],[1411,1434,1435],{"intervention":1473,"totalTrials":55,"cells":1474},"Invitae Multi-Cancer Panel ®",{"EARLY_PHASE1":1475,"PHASE1":1477,"PHASE2":1479,"PHASE3":1481,"PHASE4":1483,"NA":1485},{"trials":1476,"activeCount":59},[],{"trials":1478,"activeCount":59},[],{"trials":1480,"activeCount":59},[],{"trials":1482,"activeCount":59},[],{"trials":1484,"activeCount":59},[],{"trials":1486,"activeCount":59},[1487],{"nctId":1488,"briefTitle":1489,"status":118,"phases":1490,"primaryCompletion":562,"completion":562,"start":1491,"enrollment":1492,"conditions":1493,"interventions":1496},"NCT05305001","Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico",[],"2020-09-09",107,[1494,1495],"Pancreatic Cancer","Pancreatic Adenocarcinoma",[1473],{"intervention":1498,"totalTrials":55,"cells":1499},"Optional collection of tissue, blood and urine for future biomedical research",{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1506,"PHASE4":1508,"NA":1510},{"trials":1501,"activeCount":59},[],{"trials":1503,"activeCount":59},[],{"trials":1505,"activeCount":59},[],{"trials":1507,"activeCount":59},[],{"trials":1509,"activeCount":59},[],{"trials":1511,"activeCount":59},[1512],{"nctId":1513,"briefTitle":1514,"status":267,"phases":1515,"primaryCompletion":1516,"completion":1517,"start":1518,"enrollment":1519,"conditions":1520,"interventions":1522},"NCT05661292","Validation of Advanced Colorectal Neoplasm Risk Categories in a Prospective Cohort in Mexico",[],"2024-12-30","2025-03-30","2019-08-01",2000,[1521],"Colorectal Cancer Screening",[1498],{"intervention":1524,"totalTrials":55,"cells":1525},"Propanolol",{"EARLY_PHASE1":1526,"PHASE1":1528,"PHASE2":1530,"PHASE3":1532,"PHASE4":1534,"NA":1536},{"trials":1527,"activeCount":59},[],{"trials":1529,"activeCount":59},[],{"trials":1531,"activeCount":59},[],{"trials":1533,"activeCount":59},[],{"trials":1535,"activeCount":59},[],{"trials":1537,"activeCount":59},[1538],{"nctId":1539,"briefTitle":1540,"status":267,"phases":1541,"primaryCompletion":269,"completion":1542,"start":1543,"enrollment":1544,"conditions":1545,"interventions":1547},"NCT02484573","Evaluation of Intestinal Permeability in Cirrhotic Patients Before and After Treatment With Non-selective Beta Blocker (Propranolol)",[52],"2020-08","2015-05",39,[1546],"Liver Cirrhoses",[1524],{"intervention":1549,"totalTrials":55,"cells":1550},"Nitazoxanide",{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1555,"PHASE3":1557,"PHASE4":1559,"NA":1561},{"trials":1552,"activeCount":59},[],{"trials":1554,"activeCount":59},[],{"trials":1556,"activeCount":59},[],{"trials":1558,"activeCount":59},[],{"trials":1560,"activeCount":59},[],{"trials":1562,"activeCount":59},[1563],{"nctId":1564,"briefTitle":1565,"status":118,"phases":1566,"primaryCompletion":1131,"completion":120,"start":1567,"enrollment":564,"conditions":1568,"interventions":1571},"NCT01135628","Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy",[52],"2010-08",[1569,1570],"Hepatic Cirrhosis","Minimal Hepatic Encephalopathy",[1549]]